These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
1. KPTI reported Q1 losses of $2.77 per share, beating estimates. 2. Sales of $30.02 million missed the expected $35.24 million. 3. Phase 3 SENTRY trial continues positively without modifications. 4. FY2025 sales guidance remains at $140M-$155M, affirming market confidence. 5. Analysts adjusted KPTI price targets post-earnings, varying significantly.